Annovis Bio Highlights Buntanetap Development in Scientific Publication as Phase 3 Trials Progress

Annovis Bio Inc. (NYSE: ANVS) announced the publication of an article in The Scientist detailing the discovery and development of its lead drug candidate buntanetap, as the company advances ongoing Phase 3 and extension studies in Alzheimer's disease and Parkinson's disease. The article provides historical and scientific context for buntanetap's progression, with current trials showing approximately 70% enrollment in early Alzheimer's and 20% enrollment in Parkinson's, underscoring its focus on advancing neurodegenerative therapies toward key clinical and regulatory milestones.

The publication in The Scientist represents a significant scientific validation of buntanetap's mechanism of action and development pathway. Buntanetap, formerly known as posiphen, is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. This multi-target approach distinguishes buntanetap from many other neurodegenerative disease therapies that focus on single pathological proteins, potentially addressing the complex, multifactorial nature of diseases like Alzheimer's and Parkinson's more comprehensively.

Current enrollment figures in the Phase 3 trials indicate substantial progress toward completing these critical studies. The approximately 70% enrollment in early Alzheimer's disease trials and 20% enrollment in Parkinson's disease trials suggest that patient recruitment is advancing steadily despite the challenges inherent in neurodegenerative disease research. These enrollment percentages are particularly important given that successful completion of Phase 3 trials is essential for regulatory approval and eventual patient access to new treatments. The company's focus on both Alzheimer's and Parkinson's diseases simultaneously reflects a strategic approach to addressing two of the most prevalent neurodegenerative conditions affecting millions worldwide.

The scientific publication comes at a crucial time in neurodegenerative disease research, as the field seeks more effective treatments that can modify disease progression rather than merely addressing symptoms. By targeting multiple neurotoxic proteins through RNA translation inhibition, buntanetap represents a novel therapeutic approach that could potentially halt or slow disease progression in both Alzheimer's and Parkinson's patients. The mechanism addresses fundamental pathological processes shared across multiple neurodegenerative conditions, potentially offering broader therapeutic applications beyond the two diseases currently in Phase 3 trials.

For more information about Annovis Bio and its research, visit https://www.annovisbio.com. Additional news and updates relating to ANVS are available through the company's communications at https://ibn.fm/ANVS. The publication in The Scientist provides researchers, clinicians, and the scientific community with detailed insights into buntanetap's development history and scientific rationale, contributing to the broader understanding of neurodegenerative disease mechanisms and potential treatment approaches.